Erratum: ß2 adrenergic receptor polymorphisms and nocturnal blood pressure dipping status in theWisconsin Sleep Cohort Study (Journal of the American Society of Hypertension (2011) 5, 2, (114-122) DOI: 10.1016/j.jash.2011.01.005);β2 adrenergic receptor polymorphisms and nocturnal blood pressure dipping status in the Wisconsin Sleep Cohort Study

Journal of the American Society of Hypertension

Volumn 5, Issue 2, 2011, Pages 114-122

  Vardeny, Orly ^a   Peppard, Paul E ^b   Finn, Laurel A ^b   Faraco, Juliette H ^c   Mignot, Emmanuel ^c   Hla, Khin Mae ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ambulatory blood pressure; Single nucleotide polymorphisms; sympathetic nervous system

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE FLUCTUATION; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; FEMALE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NIGHT SLEEP; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP WAKING CYCLE;

EID: 79952732571     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2011.04.001     Document Type: Erratum

References (40)

1. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 2006;354(22):2368-74.
2. O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers. Lancet 1988;2(8607):397.
3. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005;46(1):156-61. (Pubitemid 40946507)
4. Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N, Minami N, et al. Prediction of mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements: a pilot study in Ohasama. J Hypertens 1997;15(4):357-64. (Pubitemid 27187138)
5. Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N, Minami N, et al. Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. Am J Hypertens 1997;10(11):1201-7. (Pubitemid 28005341)
6. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002;347(11):797-805. (Pubitemid 34988338)
7. Davidson MB, Hix JK, Vidt DG, Brotman DJ. Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate. Arch Intern Med 2006;166(8):846-52.
8. Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001;38(4):852-7. (Pubitemid 34258682)
9. Sica DA. What are the influences of salt, potassium, the sympathetic nervous system, and the renin-angiotensin system on the circadian variation in blood pressure? Blood Press Monit 1999;4(Suppl 2):S9-16.
10. Linsell CR, Lightman SL, Mullen PE, Brown MJ, Causon RC. Circadian rhythms of epinephrine and norepinephrine in man. J Clin Endocrinol Metab 1985;60(6):1210-5. (Pubitemid 15064783)
11. Filigheddu F, Reid JE, Troffa C, PinnaParpaglia P, Argiolas G, Testa A, et al. Genetic polymorphisms of the beta-adrenergic system: association with essential hypertension and response to beta-blockade. Pharmacogenomics J 2004;4(3):154-60. (Pubitemid 38786553)
12. Pacanowski MA, Gong Y, Cooper-Dehoff RM, Schork NJ, Shriver MD, Langaee TY, et al. beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 2008;84(6):715-21.
13. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 2005;294(12):1526- 33. (Pubitemid 41362690)
14. Vardeny O, Detry MA, Moran JJ, Johnson MR, Sweitzer NK. The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker. J Cardiovasc Pharmacol 2008;52(6):500-6.
15. Taylor MR, Bristow MR. The emerging pharmacogenomics of the beta-adrenergic receptors. Congest Heart Fail 2004;10(6):281-8.
16. Kobilka BK, Dixon RA, Frielle T, Dohlman HG, Bolanowski MA, Sigal IS, et al. cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci U S A 1987;84(1):46-50. (Pubitemid 17013575)
17. Hawkins GA, Tantisira K, Meyers DA, Ampleford EJ, Moore WC, Klanderman B, et al. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 2006;174(10):1101-9. (Pubitemid 44772080)
18. Hallmayer J, Faraco J, Lin L, Hesselson S, Winkelmann J, Kawashima M, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009;41(6):708-11.
19. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328(17):1230-5. (Pubitemid 23115702)
20. Hla KM, Young TB, Bidwell T, Palta M, Skatrud JB, Dempsey J. Sleep apnea and hypertension. A population-based study. Ann Intern Med 1994;120(5):382-8.
21. Dorn GW 2nd. Adrenergic signaling polymorphisms and their impact on cardiovascular disease. Physiol Rev 2010;90(3):1013-62.
22. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560-72. (Pubitemid 37430158)
23. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985;313(21):1315-22. (Pubitemid 16206020)
24. Cohen MC, Rohtla KM, Lavery CE, Muller JE, Mittleman MA. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol 1997;79(11):1512-6. (Pubitemid 27251072)
25. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999;282(6):539-46. (Pubitemid 29380290)
26. Rizzoni D, Muiesan ML, Montani G, Zulli R, Calebich S, Agabiti-Rosei E. Relationship between initial cardiovascular structural changes and daytime and nighttime blood pressure monitoring. Am J Hypertens 1992;5(3):180-6.
27. Sherwood A, Steffen PR, Blumenthal JA, Kuhn C, Hinderliter AL. Nighttime blood pressure dipping: the role of the sympathetic nervous system. Am J Hypertens 2002;15(2 Pt 1):111-8. (Pubitemid 34161084)
28. Bray MS, Krushkal J, Li L, Ferrell R, Kardia S, Sing CF, et al. Positional genomic analysis identifies the beta(2)-adrenergic receptor gene as a susceptibility locus for human hypertension. Circulation 2000;101(25):2877-82.
29. Masuo K, Katsuya T, Fu Y, Rakugi H, Ogihara T, Tuck ML. Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation 2005;111(25):3429-34. (Pubitemid 40923396)
30. Snieder H, Dong Y, Barbeau P, Harshfield GA, Dalageogou C, Zhu H, et al. Beta2-adrenergic receptor gene and resting hemodynamics in European and African American youth. Am J Hypertens 2002;15(11):973-9. (Pubitemid 35217403)
31. Wallerstedt SM, Eriksson AL, Ohlsson C, Hedner T. Haplotype association analysis of the polymorphisms Arg16Gly and Gln27Glu of the adrenergic beta2 receptor in a Swedish hypertensive population. J Hum Hypertens 2005;19(9):705-8. (Pubitemid 43118093)
32. Herrmann SM, Nicaud V, Tiret L, Evans A, Kee F, Ruidavets JB, et al. Polymorphisms of the beta2 adrenoceptor (ADRB2) gene and essential hypertension: the ECTIM and PEGASE studies. J Hypertens 2002;20(2):229-35. (Pubitemid 34913787)
33. Kato N, Sugiyama T, Morita H, Kurihara H, Sato T, Yamori Y, et al. Association analysis of beta (2)-adrenergic receptor polymorphisms with hypertension in Japanese. Hypertension 2001;37(2):286-92.
34. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994;33(32):9414-9. (Pubitemid 24272896)
35. Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 2001;345(14):1030-5.
36. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999;274(18):12670-4.
37. Bengtsson K, Melander O, Orho-Melander M, Lindblad U, Ranstam J, Råstam L, et al. Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation 2001;104(2):187-90.
38. Shioji K, Kokubo Y, Mannami T, Inamoto N, Morisaki H, Mino Y, et al. Association between hypertension and the alpha-adducin, beta1-adrenoreceptor, and G-protein beta3 subunit genes in the Japanese population; the Suita study. Hypertens Res 2004;27(1):31-7. (Pubitemid 38208419)
39. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003;74(1):44-52. (Pubitemid 36776175)
40. Karlsson J, Lind L, Hallberg P, Michaëlsson K, Kurland L, Kahan T, et al. Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension. Clin Cardiol 2004;27(6):347-50. (Pubitemid 38703089)